Victoria Socha

DocwireNews

The DIALIZE China (Reduce Incidence of Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Subjects) study was designed to evaluate the use of sodium zirconium cyclosilicate (SZC) for the management of hyperkalemia in patients in China undergoing hemodialysis (NCT04217590). Zhaohui Ni, MD, and colleagues reported results of the double-blind study.The study cohort included adults in China with kidney failure and predialysis hyperkalemia, (predialysis serum potassium concentration &gt;5.4 mmol/L after the long interdialytic interval [LIDI] and &gt;5.0 mmol/L after &ge;1 short interdialytic interval) who were receiving hemodialysis three times weekly. Participants were randomized to placebo or SZC 5 grams once daily on nondialysis days.Doses were titrated toward maintaining normokalemia for 4 week (titration period) in 5 gram increments up to 15 grams. The primary efficacy outcome of interest was the proportion of responders during the 4-week valuation period following the titration period. Responders were defined as those with a predialysis serum potassium concentration of 4.0 to 5.0 mmol/L for at least three of four hemodialysis visits following the LIDI who did not require urgent rescue therapy.A total of 143 adults were randomized to SZC (n=67) or placebo (n=67). Mean age was 55 years. The proportion of responders was significantly higher in the SZC group than in the placebo group: 37.3% versus 10.4%, respectively (estimated odds ratio [OR], 5.10; 95% CI, 1.90-15.15; P&lt;.001). The probability of all predialysis serum potassium concentrations being 3.5 to 5.5 mmol/L was significantly higher with SZC versus placebo (estimated OR, 6.41; 95% CI, 2.71-15.12; P&lt;.001).The proportion of patients who achieved a serum potassium concentration of 3.5 to 5.5 mmol/L on at least three of four LIDI visits during evaluation was higher in the SZC group than in the placebo group (73.1% vs 29.9%, respectively). Serious adverse events were reported in 9.1% and 11.9% of patients in the SZC group and placebo group, respectively.In conclusion, the researchers said, &ldquo;SZC treatment for predialysis hyperkalemia is effective and well tolerated in Chinese patients with kidney failure receiving hemodialysis.&rdquo;Source: <a href="https://www.clinicaltherapeutics.com/article/S0149-2918(23)00153-4/fulltext" target="_blank" rel="noopener">Clinical Therapeutics</a>

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

Findings From DIALIZE China Reported

Hyperkalemia

Results of a study designed to evaluate SZC for the management of hyperkalemia in patients undergoing dialysis.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe